It also detects MECOM rearrangements, which are well-known class-defining cytogenetics and adverse prognostic markers in AML, as well as MEF2D rearrangements in B-ALL, a class-defining lesion with diagnostic and treatment implications. Here, MECOM is linked to acute myeloid leukemia.